TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Topical 0.5% Levofloxacin to Reduce the Conjunctival Bacterial Flora Before Intraocular Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing surgery for cataract, glaucoma or vitrectomy~Exclusion Criteria:~* Patients who report to be allergic to levofloxacin or iodine~* Patients on topical antibiotic within the last 30 days~* Patients with acute conjunctivitis, blepharitis or dacryocystitis~* Patients under age of 18 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Laser Ablation Versus Mechanochemical Ablation Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 18 or over~* Symptomatic SVI which will likely benefit from treatment in the opinion of an experienced specialist and the participant~* Clinical grades C2-C6 on the CEAP system~* Superficial axial incompetence with proposed treatment lengths of at least 10cm~* Treatment with either endovenous laser ablation or mechanochemical ablation is technically feasible in the view of an experienced endovenous specialist~* Patient is willing to participate (including acceptance of randomisation to either treatment) and give valid, informed consent in the English language~Exclusion Criteria:~* One of the treatments is thought to be preferable by either the patient or an experienced endovenous specialist~* Unwilling or inability to comply with the requirements for follow-up visits~* Known allergy to medications or dressings used in the treatment~* Known right to left circulatory shunt~* Evidence of acute deep venous thrombosis or complete ipsilateral occlusion~* Pelvic vein insufficiency~* Active or recent thrombophlebitis (within 6 weeks)~* Impalpable foot pulses with an Ankle-Brachial Pressure Index of less than 0.8~* Pregnancy or breast feeding~* Active malignancy~* Immobility~* Involvement in other CTIMP trials within the last 6 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- EndoVenous Laser Ablation (Type: ACTIVE_COMPARATOR): EndoVenous Laser Ablation (EVLA) involves the delivery of laser light through a glass fibre placed into the lumen of a refluxing vein. This energy is converted into heat inducing a permanent, non-thrombotic occlusion.
- MechanoChemical Ablation (ClariVein®) (Type: ACTIVE_COMPARATOR): Mechanochemical ablation (MOCA) is performed by a device called ClariVein® which is a long thin catheter that is passed up inside the vein, with a rotating wire that protrudes at an angle from the end when deployed. This is motorised via an electric motor in the handle and rotates at approximately 3500 revolutions per minute. In addition, liquid sclerotherapy is injected at the handle end by a syringe. This sclerotherapy liquid emerges from the end of the catheter and is present in the area of the rotating tip.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Study Comparing Basic Performance and Hemocompatibility of 3 Different Dialyzers in Hemodialysis Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* ESRD patients 18 years or older~* Stable on hemodialysis for more than 3 months~* Stable hemoglobin between 11-12 g/dl~* Stable arteriovenous (AV) fistula vascular access~* Stable anticoagulation and ESA regimen~* No active infection~* Able to sign informed consent and able to participate in the study~* Medically stable~Exclusion Criteria:~* Participation in another study which may interfere with the planned study~* Active infection~* Medical conditions which may interfere with the study (cardiac, liver disease, Hepatitis)~* Allergy to dialyzer membrane materials e.g. polysulfone~* Patients which cannot tolerate Heparin~* Female who are pregnant or planning to be pregnant~* Problem with or allergy to anticoagulation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Solute Clearance (Type: ACTIVE_COMPARATOR): Solute clearance at 60 minutes for urea, creatinine, phosphate, beta 2 microglobulin, and myoglobin will be determined three times for ELISIO-15H, Revaclear and Optiflux 160NR dialyzers at the 60 minute time point.
- Hemocompatibility (Type: ACTIVE_COMPARATOR): Hemocompatibility will be determined using the markers C3a, C5a, thrombin/anti-thrombin complex and complete blood count with platelets will be determined one time for each dialyzer at session 2 and at time points 0, 15, 30, 60, and 240 minutes for ELISIO-15H, Revaclear and Optiflux 160NR dialyzers ..
- Solute removal rate (Type: ACTIVE_COMPARATOR): Solute (urea, creatinine, phosphate, beta 2 macroglobulin, and myoglobin) removal rate will be determined time points 0 and 240 minutes for ELISIO-15H, Revaclear and Optiflux 160NR dialyzers .

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Radiotherapy Versus Radiotherapy Plus Chemotherapy in Early Stage Follicular Lymphoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients (≥ 18 years old) with histologically documented follicular lymphoma, grade 1, grade 2, or follicular lymphoma, grade 3a diagnosed following an excisional, incisional or generous core biopsy. (i.e. an FNA alone is insufficient.)~* Disease limited to stages I and II after adequate staging~* Anticipated life expectancy \> 5 years~* Given written informed consent~* Been assessed by a radiation oncologist and a medical oncologist/ haematologist~* WCC \> 3.0 x 10\^9/L, platelet count \> 100 x 10\^9/L, serum creatinine \< 0.15 mmol/L~* Ability to commence radiotherapy within 6 weeks of randomisation~* Women using effective contraception, are not pregnant and agree not to become pregnant during participating in the trial and during the 12 months thereafter. Men agree not to father a child during participation in the trial and during the 12 months thereafter.~Exclusion Criteria:~* Received previous systemic cytotoxic chemotherapy.~* Received previous radiotherapy, (except superficial radiation therapy for non-melanoma skin cancers).~* Received previous immunotherapy.~* A medical contraindication to radiotherapy, chemotherapy, or rituximab.~* Any previous or concurrent malignancy other than curatively treated non-melanoma skin cancer, level 1 malignant melanoma, or in situ cervical cancer, unless disease and treatment-free for 5 years.~* Such extensive involvement of the thorax that treatment with radiation therapy alone would be hazardous because of excessive lung irradiation, even if a shrinking field technique were employed.~* Suspected or confirmed pregnancy. Must not be lactating.~* Patients who have known human immuno-deficiency virus (HIV) infection or active hepatitis B (HBV).~* Treatment within a clinical study within 30 days prior to study entry.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Radiotherapy+ Chemotherapy (Type: EXPERIMENTAL): Involved field Radiotherapy (RT) 30-36 GY plus Cyclophosphamide, Vincristine and Prednisolone (CVP) + rituximab × 6 cycles
- Radiotherapy alone (Type: ACTIVE_COMPARATOR): Involved field Radiotherapy (30-36 GY) alone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) in Subjects With Type 2 Diabetes Mellitus Using Two Different Titration Algorithms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes mellitus~* Male or female equal to or above 18 years of age~* HbA1c (glycosylated haemoglobin) 7.0 - 10.0% \[53 mmol/mol - 86 mmol/mol\] (both inclusive), confirmed by the central laboratory~* Stable daily treatment with metformin (above or equal to 1500 mg or max tolerated dose) with or without pioglitazone (above orequal to 30 mg) for at least 90 days prior to screening~* Body Mass Index (BMI) below or equal to 40 kg/m\^2~Exclusion Criteria:~* Current use of any anti-diabetic drugs (except for metformin and pioglitazone) or anticipated change in concomitant medication, which, in the opinion of the investigator, could interfere with the glucose metabolism (e.g. systemic corticosteroids)~* Previous and / or current treatment with insulin (short term treatment due to intercurrent illness, including gestational diabetes, is allowed at the discretion of the investigator)~* Treatment with glucagon-like peptide-1 (GLP-1) receptor agonists, sulpfonylurea, glinides, dipeptidyl peptidase 4 (DPP-4) inhibitors or sodium-glucose co-transporter 2 (SGLT2) inhibitors within 90 days prior to the screening visit~* Impaired liver function, defined as alanine aminotransferase (ALAT) above or equal to 2.5 times upper normal range (UNR)~* Impaired renal function defined as serum-creatinine above or equal to 133 micromol/L (above or equal to 1.5 mg/dL) for males and above or equal to 125 micromol/L (above or equal to 1.4 mg/dL) for females, or as defined according to local contraindications for metformin~* Screening calcitonin above or equal to 50 ng/L~* Proliferative retinopathy or maculopathy (macular oedema) requiring acute treatment, according to investigator's clinical judgment~* Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2)~* History of pancreatitis (acute or chronic)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Once weekly titration (Type: EXPERIMENTAL): None
- Twice weekly titration (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Physical Therapy Treatment Once a Month Versus Once a Week for Posture Improvement in Children and Adolescents

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Children and Adolescent who referred by their pediatrician or orthopedic doctor to Physical Therapy treatment due to bad posture or Low Back Pain~2. At the Physical Therapy clinic was found that this is truly the condition of bad posture or low back pain with bad posture.~3. age 10-18 years~4. they signed on informed consent.~Exclusion Criteria:~1. Children and Adolescent who suffer from risk of structural deterioration as structural scoliosis(Cob angle above 20° and Risser sign equal or below 3) or structural Kyphosis (above 40° Risser sign equal or below 3 or Scheuermann Disease)~2. Any sever health condition neurologic internal or orthopedic like Cerebral Palsy, Juvenile rheumatoid arthritis or Malignancy.

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 18 Years
- Healthy Volunteers: t

Study Arms:
- Once a month and once a week. (Type: EXPERIMENTAL): Personally meeting once a month of Physical Therapy treatment for Postural Behavior.~In addition exercise group meeting once a week. The intervention program will include physical awareness by using a mirror and practice for good posture, and exercises for flexibility, strength and muscle endurance.~All participants will get 10-15 minutes of exercise for performing every day. The Participants in this group will get also a group exercise meeting once a week That meeting will long 45 minutes and will include the exercise that were given as home work and more.~Total duration 12 weeks/3 months
- Once a month only. (Type: ACTIVE_COMPARATOR): Personally meeting once a month only for Physical Therapy treatment for Postural Behavior.~The intervention program will include physical awareness by using a mirror and practice for good posture, and exercises for flexibility, strength and muscle endurance.~All participants will get 10-15 minutes of exercise for performing every day. Total duration 12 weeks/3 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability, and Efficacy of GS-9876 in Participants With Active Rheumatoid Arthritis on Background Therapy With Methotrexate

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Key Inclusion Criteria:~* Active RA disease as defined by: a tender joint count (TJC) of ≥ 6 (out of 68), a swollen joint count (SJC) of ≥ 6 (out of 66) at screening and Day 1~* Inadequate response to treatment with oral or parenteral methotrexate (MTX) 7.5 to 25 mg/week continuously for at least 12 weeks~* No evidence of active or latent tuberculosis~Key Exclusion Criteria:~* Prior treatment with B-cell depleting agents (eg, rituximab), unless more than 6 months prior to the first dose of study drug and documented return of CD19+ cells at screening~* Prior treatment with any commercially available or investigational spleen tyrosine kinase (SYK) inhibitor~* Concurrent treatment with any other conventional synthetic DMARD (csDMARD) other than MTX and/or hydroxychloroquine (HCQ) (prior csDMARD treatment allowed if appropriate wash out as defined in the protocol)~* Concurrent treatment with any biological disease modifying anti-rheumatic drug (bDMARD)(prior bDMARD treatment allowed if appropriate wash out as defined in the protocol). Prior failure to treatment with bDMARDs is not an exclusion criterion.~Note: Other protocol defined Inclusion/ Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- GS-9876 - 30 mg (Type: EXPERIMENTAL): GS-9876 30 mg + filgotinib placebo for 12 weeks
- GS-9876 - 10 mg (Type: EXPERIMENTAL): GS-9876 10 mg + filgotinib placebo for 12 weeks
- Filgotinib (Type: EXPERIMENTAL): Filgotinib + GS-9876 placebo for 12 weeks
- Placebo (Type: PLACEBO_COMPARATOR): GS-9876 placebo + filgotinib placebo for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study on Rituximab (MabThera) in Participants With Chronic Lymphocytic Leukemia (CLL)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* CLL requiring treatment~* Participants receiving a chemotherapy in combination with rituximab (decision taken by doctor prior to and independent from inclusion in this non-interventional study)~* After this trial started, an amendment to the study protocol was introduced, adding a further inclusion criterion: Comorbidities according to cumulative illness rating scale (CIRS) score greater than (\>) 6 and/or creatinine clearance less than (\<) 70 milliliters per minute (mL/min)~Exclusion Criteria:~* Participants with contraindication to rituximab treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Participants With CLL (Type: None): Participants with CLL who are being treated with intravenous (IV) rituximab in combination with chemotherapy, will be observed for 24 months including 6-month treatment period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: PALACE 3: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Males or females, aged ≥ 18 years at time of consent.~* Have a diagnosis of Psoriatic Arthritis (PsA, by any criteria) of ≥ 6 months duration.~* Meet the Classification Criteria for Psoriatic Arthritis (CASPAR) criteria for PsA at time of screening.~* Must have been inadequately treated by disease-modifying antirheumatic drugs (DMARDs)~* May not have axial involvement alone~* Concurrent Tx allowed with methotrexate, leflunomide, or sulfasalazine~* Have ≥ 3 swollen AND ≥ 3 tender joints.~* Males \& Females must use contraception~* Stable dose of NSAIDs, narcotics and low dose oral corticosteroids allowed.~* Have at least one ≥2 cm psoriasis lesion~Exclusion Criteria:~* Pregnant or breast feeding.~* History of allergy to any component of the investigational product Hepatitis B surface antigen and/or Hepatitis C antibody positive at screening.~* Therapeutic failure on \> 3 agents for PsA or \> 1 biologic tumor necrosis factor (TNF) blocker

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Apremilast 20 mg (Type: EXPERIMENTAL): 20 mg Apremilast tablets administered twice daily for 24 weeks during the placebo-controlled phase followed by 20 mg Apremilast tablets administered twice daily for up to 4.5 years in the active treatment / long-term safety phase
- Apremilast 30 mg (Type: EXPERIMENTAL): 30 mg Apremilast tablets administered twice a day for 24 weeks during the placebo-controlled phase followed by 30 mg Apremilast tablets administered twice a day for up to 4.5 years in the active treatment / long-term safety phase orally twice daily
- Placebo + 20 mg Apremilast (Type: PLACEBO_COMPARATOR): Placebo + 20 mg Apremilast tablets administered twice daily for 24 weeks during the placebo-controlled phase followed by 20 mg Apremilast tablets administered twice daily for up to 4.5 years in the active treatment / long-term safety phase. Subjects who do not have at least 20% improvement in their swollen and tender joint counts at Week 16 will escape to 20 mg Apremilast twice daily at Week 16
- Placebo + 30 mg Apremilast (Type: PLACEBO_COMPARATOR): Placebo + 30 mg Apremilast tablets administered twice daily for 24 weeks during the placebo-controlled phase followed by 30 mg Apremilast tablets administered twice daily for up to 4.5 years in the active treatment / long-term safety phase. Subjects who do not have at least 20% improvement in their swollen and tender joint counts at Week 16 will escape to 30 mg Apremilast twice daily at Week 16.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dose-finding of Lenalidomide as Maintenance in Multiple Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Understand and voluntarily sign informed consent form~* Age \> 18 years at the time of signing the informed consent form~* Able to adhere to the study visit schedule and other protocol requirements~* Multiple myeloma patients who received allogeneic stem cell transplantation (100 to 180 days ago)~* No active acute GvHD (grade II - IV)~* No active infectious complications~* ECOG performance status of \< 2 at study entry~* Laboratory test results within these ranges:~  * Absolute WBC count \> 3.0 x 10\^9/l~ * Platelet count \> 80 x 10\^9/l~ * Serum creatinine \< 1.5 mg/dl~ * Total bilirubin \< 1,5 mg/dl~ * AST (SGOT) and ALT (SGPT) \< 3 x ULN~* Females of childbearing potential must agree to use two reliable forms of contraception simultaneously or to practice complete abstinence from heterosexual intercourse for at least 28 days before starting study drug, while participating in the study and at least 28 days after discontinuation from the study.~* male subjects must agree to use a latex condom during sexual contact with females of childbearing potential while participating in the study and for at least 28 days after discontinuation of study drug~* disease free of prior malignancies for \> 5 years with exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma in situ of the cervix or breast~Exclusion Criteria:~* Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form~* pregnant or breast feeding females~* use of any other experimental drug or therapy within 28 days of baseline~* known hypersensitivity to thalidomide~* concurrent use of other anti-cancer agents or treatments~* known positive for HIV of infectious hepatitis, type A, B, or C

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Lenalidomide-treatment starts between 100 and 180 days after allogeneic stem cell transplantation. Three dose-levels will be investigated.~* Dose-level -1: 2.5 mg/d if 2.5mg capsules are available, day 1-21, otherwise 5 mg every other day, day 1-21~* Dose-level 0: 5 mg/d, day 1-21~* Dose-level 1: 10 mg/d, day 1-21~* Dose-level 2: 15 mg/d, day 1-21

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete